Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Grossberg, A.J.; Chu, L.C.; Deig, C.R.; Fishman, E.K.; Hwang, W.L.; Maitra, A.; Marks, D.L.; Mehta, A.; Nabavizadeh, N.; Simeone, D.M.; et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J. Clin. 2020, 70, 375–403. [Google Scholar] [CrossRef]
- Hu, J.X.; Zhao, C.F.; Chen, W.B.; Liu, Q.C.; Li, Q.W.; Lin, Y.Y.; Gao, F. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J. Gastroenterol. 2021, 27, 4298–4321. [Google Scholar] [CrossRef] [PubMed]
- Burris, H.A., 3rd; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 1997, 15, 2403–2413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oettle, H.; Neuhaus, P.; Hochhaus, A.; Hartmann, J.T.; Gellert, K.; Ridwelski, K.; Niedergethmann, M.; Zülke, C.; Fahlke, J.; Arning, M.B.; et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA 2013, 310, 1473–1481. [Google Scholar] [CrossRef] [Green Version]
- Neoptolemos, J.P.; Palmer, D.H.; Ghaneh, P.; Psarelli, E.E.; Valle, J.W.; Halloran, C.M.; Faluyi, O.; O’Reilly, D.A.; Cunningham, D.; Wadsley, J.; et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. Lancet 2017, 389, 1011–1024. [Google Scholar] [CrossRef] [Green Version]
- Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013, 369, 1691–1703. [Google Scholar] [CrossRef] [Green Version]
- Conroy, T.; Hammel, P.; Hebbar, M.; Ben Abdelghani, M.; Wei, A.C.; Raoul, J.L.; Choné, L.; Francois, E.; Artru, P.; Biagi, J.J.; et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N. Engl. J. Med. 2018, 379, 2395–2406. [Google Scholar] [CrossRef]
- Conroy, T.; Castan, F.; Lopez, A.; Turpin, A.; Ben Abdelghani, M.; Wei, A.C.; Mitry, E.; Biagi, J.J.; Evesque, L.; Artru, P.; et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol. 2022, 8, 1571–1578. [Google Scholar] [CrossRef]
- Suker, M.; Beumer, B.R.; Sadot, E.; Marthey, L.; Faris, J.E.; Mellon, E.A.; El-Rayes, B.F.; Wang-Gillam, A.; Lacy, J.; Hosein, P.J.; et al. FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis. Lancet Oncol. 2016, 17, 801–810. [Google Scholar] [CrossRef]
- Murphy, J.E.; Wo, J.Y.; Ryan, D.P.; Jiang, W.; Yeap, B.Y.; Drapek, L.C.; Blaszkowsky, L.S.; Kwak, E.L.; Allen, J.N.; Clark, J.W.; et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018, 4, 963–969. [Google Scholar] [CrossRef] [Green Version]
- Okabayashi, T.; Sui, K.; Tabuchi, M.; Murokawa, T.; Sakamoto, S.; Iwata, J.; Morita, S.; Okamoto, N.; Iiyama, T.; Shimada, Y.; et al. Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. J. Clin. Med. 2022, 11, 6792. [Google Scholar] [CrossRef]
- Zwart, E.S.; Yilmaz, B.S.; Halimi, A.; Ahola, R.; Kurlinkus, B.; Laukkarinen, J.; Ceyhan, G.O. Venous resection for pancreatic cancer, a safe and feasible option? A systematic review and meta-analysis. Pancreatology 2022, 22, 803–809. [Google Scholar] [CrossRef]
- Wang, W.; He, Y.; Wu, L.; Ye, L.; Yao, L.; Tang, Z. Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma. An update meta-analysis. Pancreatology 2019, 19, 1074–1080. [Google Scholar] [CrossRef]
- Asbun, H.J.; Moekotte, A.L.; Vissers, F.L.; Kunzler, F.; Cipriani, F.; Alseidi, A.; D’Angelica, M.I.; Balduzzi, A.; Bassi, C.; Björnsson, B.; et al. The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. Ann. Surg. 2020, 271, 1–14. [Google Scholar] [CrossRef]
- Beane, J.D.; Borrebach, J.D.; Zureikat, A.H.; Kilbane, E.M.; Thompson, V.M.; Pitt, H.A. Optimal Pancreatic Surgery: Are We Making Progress in North America? Ann. Surg. 2021, 274, e355–e363. [Google Scholar] [CrossRef]
- Nagakawa, Y.; Watanabe, Y.; Kozono, S.; Boggi, U.; Palanivelu, C.; Liu, R.; Wang, S.E.; He, J.; Nishino, H.; Ohtsuka, T.; et al. Surgical approaches to the superior mesenteric artery during minimally invasive pancreaticoduodenectomy: A systematic review. J. Hepatobiliary Pancreat. Sci. 2022, 29, 114–123. [Google Scholar] [CrossRef]
- Ban, D.; Garbarino, G.M.; Ishikawa, Y.; Honda, G.; Jang, J.Y.; Kang, C.M.; Maekawa, A.; Murase, Y.; Nagakawa, Y.; Nishino, H.; et al. Surgical approaches for minimally invasive distal pancreatectomy: A systematic review. J. Hepatobiliary Pancreat. Sci. 2022, 29, 151–160. [Google Scholar] [CrossRef]
- Takagi, K.; Umeda, Y.; Yoshida, R.; Fuji, T.; Yasui, K.; Kimura, J.; Hata, N.; Mishima, K.; Yagi, T.; Fujiwara, T. Surgical Strategies to Dissect around the Superior Mesenteric Artery in Robotic Pancreatoduodenectomy. J. Clin. Med. 2022, 11, 7112. [Google Scholar] [CrossRef]
- Takagi, K.; Umeda, Y.; Yoshida, R.; Yagi, T.; Fujiwara, T.; Zureikat, A.H.; Hogg, M.E.; Koerkamp, B.G. Surgical training model and safe implementation of robotic pancreatoduodenectomy in Japan: A technical note. World J. Surg. Oncol. 2021, 19, 55. [Google Scholar] [CrossRef]
- Takagi, K.; Umeda, Y.; Yoshida, R.; Yagi, T.; Fujiwara, T. Robotic Radical Antegrade Modular Pancreatosplenectomy Using the Supracolic Anterior Superior Mesenteric Artery Approach. J. Gastrointest. Surg. 2021, 25, 3015–3018. [Google Scholar] [CrossRef] [PubMed]
- Takagi, K.; Kumano, K.; Umeda, Y.; Yoshida, R.; Fuji, T.; Yasui, K.; Yagi, T.; Fujiwara, T. Surgical Strategies to Approaching the Splenic Artery in Robotic Distal Pancreatectomy. Anticancer Res. 2022, 42, 4471–4476. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Takagi, K.; Umeda, Y.; Yoshida, R.; Fuji, T.; Yasui, K.; Yagi, T.; Fujiwara, T. Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. J. Clin. Med. 2023, 12, 465. https://doi.org/10.3390/jcm12020465
Takagi K, Umeda Y, Yoshida R, Fuji T, Yasui K, Yagi T, Fujiwara T. Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. Journal of Clinical Medicine. 2023; 12(2):465. https://doi.org/10.3390/jcm12020465
Chicago/Turabian StyleTakagi, Kosei, Yuzo Umeda, Ryuichi Yoshida, Tomokazu Fuji, Kazuya Yasui, Takahito Yagi, and Toshiyoshi Fujiwara. 2023. "Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment" Journal of Clinical Medicine 12, no. 2: 465. https://doi.org/10.3390/jcm12020465
APA StyleTakagi, K., Umeda, Y., Yoshida, R., Fuji, T., Yasui, K., Yagi, T., & Fujiwara, T. (2023). Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. Journal of Clinical Medicine, 12(2), 465. https://doi.org/10.3390/jcm12020465